多発性硬化症およびその他の疾患におけるスフィンゴシン1-リン酸受容体調節剤
Marisa P McGinley1, Jeffrey A Cohen1
1Mellen Center, Cleveland Clinic, Cleveland, OH, USA.
Lancet (London, England)
|June 27, 2021
まとめ
Sphingosine 1- phosphate (S1P) 受容体調節剤は,循環中のリンパ球を減少させることで,多発性硬化症の治療に承認されています. 更に研究が進められれば 他の治療の応用の可能性も明らかになります
科学分野:
- 免疫学
- 薬理学について
- 神経科学
背景:
- Sphingosine 1-phosphate (S1P) のシグナル伝達経路は,重要な生理学的プロセスを調節する.
- S1P受容体 (S1PRs) はリンパ球の流通,免疫反応,臓器機能に関与している.
- S1PRは様々な病気の治療標的として認識されています.
研究 の 目的:
- 多発性硬化症における S1PR 調節体の役割を検討する.
- 多発性硬化症以外の S1PR 調節器の治療の可能性を探る
主な方法:
- S1PR 調節器に関する科学文献のレビュー
- 臨床試験前データと臨床試験結果の分析
- 多発性硬化症におけるS1PR作用機構の検討
主要な成果:
- 4つのS1PR調節剤 (フィンゴリモド,シポニモド,オザニモド,ポネシモド) は多発性硬化症の治療に承認されています.
- 多発性硬化症の主なメカニズムは,S1PR1がリンパ球に内蔵され,中枢神経の炎症を軽減することです.
- 臨床前および臨床的証拠は,より広範な治療用途を示唆しています.
結論:
- S1PR調節器は多発性硬化症の治療において 重要な進歩を示しています
- S1Pシグナル伝達の多様な役割は,他の疾患におけるS1PR調節器の有望な将来を示しています.
- 現在進行中の研究は,S1PR調節器の治療分野を拡大し続けています.
さらに関連する動画
04:55A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
4.2K
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
4.2K
関連する概念動画
01:28Classification of Skeletal Muscle Relaxants
2.8K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
561
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
561
01:29Spasmolytic Agents: Chemical Classification
1.1K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.1K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.1K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.0K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.0K
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
958
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
958